Tag: AL amyloidosis
Janssen secures DARZALEX FASPRO FDA approval for AL amyloidosis
DARZALEX FASPRO FDA approval for AL amyloidosis : Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has secured approval from the US Food and Drug ... Read More
Janssen seeks EMA’s expanded approval for DARZALEX in AL amyloidosis
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency (EMA) seeking the expanded approval ... Read More